US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.73

-0.1253-0.32%

Post-market: 38.880.1468+0.38%19:30 EDT

Volume:20.10K

Turnover:779.86K

Market Cap:355.14M

PE:- -

High:38.94

Open:38.73

Low:38.61

Close:38.85

52wk High:39.80

52wk Low:30.66

Shares:9.17M

Float Shares:9.17M

Volume Ratio:0.56

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Press Release: InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

Press Release: BeyondSpring Reports 2025 Year-End Financial Results

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/ORR/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.7288,"timestamp":1789416000000,"preClose":38.8541,"halted":0,"volume":20104,"hourTrading":{"tag":"盘后","latestPrice":38.8756,"preClose":38.7288,"latestTime":"19:30 EDT","volume":254,"amount":9872.1379,"timestamp":1789428600910,"change":0.1468,"changeRate":0.00379,"amplitude":0.003759},"delay":0,"changeRate":-0.003224884889882994,"floatShares":9170000,"shares":9170000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.1253,"latestTime":"09-14 16:00:00 EDT","open":38.73,"high":38.94,"low":38.605,"amount":779860.7978000001,"amplitude":0.008622,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":38.8541,"sharesOutstanding":12900000,"nav":38.64,"aum":354328800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.73,"preClose":38.8541,"latestTime":"08:26 EDT","volume":80,"amount":3089.79984,"timestamp":1789388809207,"change":-0.1241,"changeRate":-0.003194,"amplitude":0.011067},"postHourTrading":{"tag":"盘后","latestPrice":38.8756,"preClose":38.7288,"latestTime":"19:30 EDT","volume":254,"amount":9872.1379,"timestamp":1789428600910,"change":0.1468,"changeRate":0.00379,"amplitude":0.003759},"volumeRatio":0.564821,"impliedVol":0.1759,"impliedVolPercentile":0.6279},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.564821,"shares":9170000,"dividePrice":0,"high":38.94,"amplitude":0.008622,"preClose":38.8541,"low":38.605,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.7288,"eps":0,"divideRate":0,"volume":20104,"delay":0,"ttmEps":0,"open":38.73,"prevYearClose":34.16,"prevWeekClose":38.8541,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":39.1863,"twentyDayClose":38.35,"sixtyDayClose":36.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG0V08.USD","PK","PD","BK4007","LU1169589451.USD","LU1721428933.USD","BK4107","LU2413666699.HKD","LU0456854461.SGD","CC","BK4121","CRC","BK4098","IE00BYQQ9H92.USD","PROC","BK4181","BK4218","IE00B5TLWC47.USD","R","BK4006","BK4022","LU2413666426.HKD","BK4156","BK4232","BK4585","LU0347712357.USD","ORR","BK4213","BK4548","BK1574","LU1093756325.SGD","LU0210528500.USD","LU1169590202.USD","LU0266512127.USD","02616","LU2211817866.USD","BK4533","MTD","BK4588","HCC","LU1093756168.USD","BK1161","BK4023","LU0053666078.USD","BK4567","LU2487616109.SGD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNA","PD","PR","BK4023","AGIX","LU1169589451.USD","BK4213","MDCX","LU1169590202.USD","CR","CHAT","BK4139","BK4215","BK4567","BK4104","AIPO","BK4161","ORR","CSR","BCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622368079","title":"Press Release: InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622368079","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622368079?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:04","pubTimestamp":1774443840,"startTime":"0","endTime":"0","summary":"BEIJING, March 25, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.2025 marked InnoCare's 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application  approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous \"China First\" achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth.-- Revenue grew 135.3% year-on-year to RMB 2,375 million1 in 2025, mainly. driven by robust commercial growth and two strategic business development. -- Profit reached RMB 644 million, achieving profitability for the first. time, mainly due to significant com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSCS","LU1244550577.SGD","IE00BVYPNV92.GBP","LU1674673428.USD","LU0823417653.USD","TLS","BK4579","LU2506952170.USD","SG9999015986.USD","BK4588","LU0234572021.USD","LU1585245621.USD","09969","LU0320765646.SGD","LU1066051225.USD","BK4525","CSCO","IE00BSNM7G36.USD","IE00B42XCP33.USD","LU1059921491.USD","LU1880398471.USD","SG9999001424.SGD","LU0234570918.USD","IE000M9KFDE8.USD","IE00BGHQF631.EUR","LU1066051498.USD","LU1235294995.USD","BK4020","IE00BVYPNW00.USD","LU1599440770.SGD","LU1032955483.USD","ORR","LU0203345920.USD","SG9999015945.SGD","CSCL","LU2237443978.SGD","SG9999015978.USD","LU2237443895.HKD","LU0792757196.USD","LU1894683264.USD","LU1894683348.USD","LU1929549753.HKD","LU2102340556.USD","LU1883839398.USD","LU2286300806.USD","LU1221951046.USD","LU1571399168.USD","LU2237443465.HKD","BK4533","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107545","title":"Press Release: BeyondSpring Reports 2025 Year-End Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107545?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:30","pubTimestamp":1774441800,"startTime":"0","endTime":"0","summary":"-- Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors. progressed after first line therapy -- DUBLIN-3 study results published. discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global. Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient. sensitivity to checkpoint inhibitors -- a significant unmet need. Cell Press journal Med 2025 and presented at SITC 2025. \"2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics,\" said Dr. Lan Huang, Co-Founder, Chairman and Chief Executive Officer of BeyondSpring. \"We advanced our Phase 3 Plinabulin program, generated meaningful clinical data, and strengthened our strategic and financial position.\". \"BeyondSpring made meaningful progress advancing Plinabulin in Phase 3 NSCLC, while SEED Therapeutics reached a critical milestone -- initiating its first clinical trial following IND cle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4139","HR","BK4195","BK4203","PFS","BYSI","OS","BK4097","ORR","BK4225"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBH","BK7095","OS","BK4211","PFS","BK4007","PK","BK4195","ORR","BK4218","BK4097","BK4181","ORR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4161","BK4007","BK4539","INNMF","LENZ","PR","CR","BK4097","PFS","BK4139","ORR","OS","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777299","title":"Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777299?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing. Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA in 1L/2L+ R/M HNSCC on track for the second half of 2026. Announced appointment of Thomas Civik as Interim Chief Executive Officer. Expected cash runway into the fourth quarter of 2026. BOSTON, March 23, 2026  -- Pyxis Oncology, Inc. , a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the year and quarter ended December 31, 2025.-- Pyxis Oncology announced positive preliminary data for micvotabart. -- Monotherapy: 46% confirmed objective response rate  and 92%. disease control rate  observed with MICVO as monotherapy in. 2L+ R/M HNSCC . MICVO as monotherapy was. generally well tolera","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4232","BK4588","ORR","LU0053666078.USD","PYXS","BK4107","BK4139","LU0210528500.USD","R","L","LU2487616109.SGD","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620779332","title":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:21","pubTimestamp":1773962460,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligibl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259513/0/en/Cellectis-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4139","CRS","ORR","CLLS","IE0031619046.USD","LU2463526074.USD","BK4109","IE00B7SZL793.SGD","BK4187","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU0963586101.USD","BK4097","LU2065731478.USD","ASH","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":128,"code":"91000000","status":"200"}]}}